GENETIC ARCHITECTURE AND MOLECULAR BIOMARKERS OF PRIMARY OPEN-ANGLE GLAUCOMA: IMPLICATIONS FOR RISK STRATIFICATION AND PERSONALIZED THERAPY
Genetics and Molecular Research · 15.07.2026
DOI: 10.4238/93v4bv62 ↗Kurz gefasst
Fachartikel in der Zeitschrift Genetics and Molecular Research, online erschienen am 15.07.2026. Verfasst von Imani Akhmadovna Makhieva und 8 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-SA 4.0).
Abstract (Originalsprache)
Introduction
Primary open-angle glaucoma (POAG) is a genetically heterogeneous optic neuropathy in which elevated intraocular pressure, retinal ganglion cell susceptibility, vascular regulation, extracellular-matrix remodeling, mitochondrial dysfunction, and immune signaling interact.
Aim
To synthesize current evidence on monogenic variants, common polygenic susceptibility, molecular biomarkers, and emerging genotype-informed therapeutic strategies in POAG. Materials and methods. A narrative review was conducted using PubMed/MEDLINE-indexed publications identified with combinations of the terms “primary open-angle glaucoma,” “genetics,” “genome-wide association study,” “polygenic risk score,” “biomarker,” “proteomics,” “microRNA,” and “gene therapy.” Priority was given to multi-ancestry genetic studies, systematic reviews, longitudinal cohorts, and experimentally validated translational studies published through July 2026.
Results
Rare variants in MYOC, OPTN, and TBK1 explain a small but clinically important fraction of familial or early-onset disease. Genome-wide analyses have identified hundreds of loci that converge on aqueous-outflow regulation, optic nerve development, vascular biology, extracellular matrix, and retinal ganglion cell survival. Polygenic risk scores are associated with disease onset, progression, and earlier need for surgery, but portability across ancestries remains limited. Candidate biomarkers in aqueous humor, tears, and blood include cytokines, complement proteins, oxidative-stress metabolites, neurotrophic factors, and microRNAs; none has yet achieved sufficient analytical and clinical validation for stand-alone diagnosis.
Conclusion
The most realistic precision-medicine model combines ancestry-calibrated genetic risk, established ocular phenotypes, and longitudinal molecular markers. Clinical implementation requires prospective validation, standardized assays, and evidence that biomarker-guided decisions improve visual outcomes.
Zitieren
APA
Makhieva, I. A., Bagichev, Z. N., Akhmedov, M. R., Magomedova, A. M., Akaev, Y. Y., Dementyeva, E. P., Utegenova, Z. S., Akhmedova, N. R., & Kindarov, D. A. (2026). GENETIC ARCHITECTURE AND MOLECULAR BIOMARKERS OF PRIMARY OPEN-ANGLE GLAUCOMA: IMPLICATIONS FOR RISK STRATIFICATION AND PERSONALIZED THERAPY. Genetics and Molecular Research. https://doi.org/10.4238/93v4bv62
Vancouver
Makhieva IA, Bagichev ZN, Akhmedov MR, Magomedova AM, Akaev YY, Dementyeva EP, et al. GENETIC ARCHITECTURE AND MOLECULAR BIOMARKERS OF PRIMARY OPEN-ANGLE GLAUCOMA: IMPLICATIONS FOR RISK STRATIFICATION AND PERSONALIZED THERAPY. Genetics and Molecular Research. 2026. doi:10.4238/93v4bv62
BibTeX
@article{Makhieva2026,
author = {Makhieva, Imani Akhmadovna and Bagichev, Zaur Narimanovich and Akhmedov, Magomed Ramazanovich and Magomedova, Aminat Magomedovna and Akaev, Yahya Yusupovich and Dementyeva, Ekaterina Pavlovna and Utegenova, Zulguzhat Shamilievna and Akhmedova, Nargiz Rayyudinovna and Kindarov, Dzhambulat Alikhanovich},
title = {GENETIC ARCHITECTURE AND MOLECULAR BIOMARKERS OF PRIMARY OPEN-ANGLE GLAUCOMA: IMPLICATIONS FOR RISK STRATIFICATION AND PERSONALIZED THERAPY},
journal = {Genetics and Molecular Research},
year = {2026},
doi = {10.4238/93v4bv62}
}
EUVIMED